# TILVANCE-301 (NCT05727904)

> Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

No report yet. It can be ordered.

- Drugs tested: lifileucel plus pembrolizumab
- Indication: untreated unresectable or metastatic melanoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05727904
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Iovance Biotherapeutics, Inc.
- Conditions: Metastatic Melanoma; Unresectable Melanoma; Melanoma
- Interventions: Lifileucel plus Pembrolizumab; Pembrolizumab with Optional Crossover Period
- Enrollment: 670
- Primary outcome: Objective Response Rate and Progression Free Survival

## Indexed commentary on TILVANCE-301 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 40 posts on X
- 3 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tilvance-301-nct05727904

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05727904", "email": "<work email>"}; the inbox owner confirms by the emailed link.
